ROTARIX offers early protection to help prevent RGE and its consequences
Only ROTARIX provides completion of the rotavirus immunization series by 4 months of age in just 2 oral doses. [1,2] ROTARIX is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series in infants and children. Click here >>
More on dosing and administration >>
ROTARIX demonstrates significant efficacy against severe RGE regardless of serotype
ROTARIX, the first fully human attenuated rotavirus vaccine, is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in infants and children. [1,2]Learn more >>
ROTARIX offers sustained efficacy against common and emerging serotypes
Through 2 seasons after vaccination, ROTARIX demonstrated significant serotype-specific efficacy against severe RGE for ALL 5 of the most common strains in the US. [1,3,8]Learn more >>
ROTARIX has a proven safety profile [1,5]
ROTARIX was studied in one of the largest clinical development plans undertaken by a vaccine manufacturer. ROTARIX is currently licensed in more than 100 countries and more than 25 million doses have been distributed. [9]Learn more >>
Learn about adverse events associated with ROTARIX
NEXT: Early Protection >>
Important Safety Information
- In clinical studies, common adverse events were fussiness/irritability, cough/runny nose, fever, loss of appetite, and vomiting.
- History of uncorrected congenital malformation of the gastrointestinal tract is a contraindication.
- Previous hypersensitivity to any component of ROTARIX, including latex rubber, should be reviewed prior to administration.
- Administration in infants suffering from acute diarrhea or vomiting should be delayed.
- Safety and effectiveness in infants with chronic gastrointestinal disorders, or with known primary or secondary immunodeficiencies, have not been evaluated.
 |
Download Complete Prescribing Information for ROTARIX |
